All Updates

All Updates

icon
Filter
Funding
SmartCella raises EUR 50 million in private funding to accelerate Extroducer development and cell and mRNA operations
Cell & Gene Therapy
Jul 8, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Jul 8, 2024

SmartCella raises EUR 50 million in private funding to accelerate Extroducer development and cell and mRNA operations

Funding

  • Biotech and medtech company SmartCella Holding has successfully raised EUR 50 million (~USD 54 million) in a new share issue. The funding round was backed by investors including Fjärde AP-fonden, AMF Pension, SEB-Stiftelsen, as well as new investors AstraZeneca, Handelsbanken Fonder, and RoosGruppen AB. This round resulted in a pre-money valuation of ~EUR 500 million (~USD 541 million).

  • The funds procured will be channeled toward the commercialization of SmartCella's Extroducer and the advancement of its cell and mRNA operations. The capital is also planned to expand the company's organizational infrastructure.

  • Sweden-based SmartCella is a global biotechnology company focused on delivering targeted therapies using its novel delivery platforms. Its portfolio includes the FDA-cleared Extroducer, an endovascular device designed for the precise delivery of therapies to challenging-to-access tumors or organs, as well as cell and mRNA therapies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.